Enrique Chacon-Cruz

Dr. Enrique Chacon-Cruz

Ministry of Health, Mexicali, Baja California, Mexico
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1998 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
LPLav K. Parvathenani
Lav K. Parvathenani
EBE. Stephen Buescher
E. Stephen Buescher
Enrique Chacon-CruzEnrique Chacon-Cruz
Enrique Chacon-Cruz
SBStephen J. Beebe
Stephen J. Beebe
Current data suggest that apoptosis controls neutrophil numbers in tissues. We analyzed roles for and the sites of action for the cAMP-dependent protein kinases (cAPKs) in apoptosis induced in human neutrophils by in vitro storage, cycloheximide (CHX) exposure, and anti-Fas exposure. Treatment with 8-chlorophenylthio-cAMP (8-CPT-cAMP) prolonged the time required for 50% of the cells to exhibit apoptotic morphology (t 50) from 16.3 to 41.8 h (in vitro culture), from 2.4 to 7.8 h (CHX), and from 4.8 to 6.5 h (anti-Fas). CHX ± 8-CPT-cAMP did not significantly alter resting intracellular calcium levels and H-89, a selective inhibitor of cAPK, had no effect on apoptosis in the absence of the analogue. In contrast, site-selective cAMP analogues that specifically activated the type I cAPK, but not type II cAPK, synergistically attenuated apoptosis. Exposure to 8-CPT-cAMP delayed, in parallel, the activity of caspase-3 (CPP-32β), whereas mitogen-activated protein kinase kinase (MAPKK) inhibitor, PD98059, had no effect on CHX-induced apoptosis ± 8-CPT-cAMP. Together these results indicate that type I cAPK activation is necessary and sufficient to mediate cAMP-induced delay in human neutrophil apoptosis induced by several mechanisms and suggest that one of the major sites of cAPK action is upstream of caspase-3 (CPP-32β) activation.

1 January 2006 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
RVRolando M Viani
Rolando M Viani
MAMaria Rosario G Araneta
Maria Rosario G Araneta
JRJorge Ruiz-Calderon
Jorge Ruiz-Calderon
PHPatricia Hubbard
Patricia Hubbard
GLGraciano Lopez
Graciano Lopez
SSStephen A Spector
Stephen A Spector
To evaluate the acceptance of counseling and rapid HIV testing and to determine the associated risk factors for HIV infection in pregnant women in Baja California, Mexico. Pregnant women attending Tijuana General Hospital who consented to participate in the study had blood drawn for a rapid HIV test (Determine HIV-1/2; Abbott Diagnostics, North Chicago, IL). A confirmatory enzyme immunoassay and Western blot were performed and demographic and risk factor data were obtained. From March to November 2003, 1529 (92.5%) of 1653 women who sought prenatal care and 1068 (95.2%) of 1122 women in labor consented to participate. HIV seroprevalence was significantly higher among women screened during labor (12/1068, 1.12%) compared with those seeking prenatal care (5/1529, 0.33%). HIV-infected women were significantly more likely to use injection drugs (12% vs. 1%, P = 0.02), "other" drugs, including methamphetamine, marijuana, and cocaine (65% vs. 6%, P < 0.001), to have more sex partners (3.6 vs. 2.6, P = 0.0002), to not have received prenatal care (41% vs. 13%, P = 0.03), and to have a spouse/partner who used injection drugs (36% vs. 4%, P < 0.001) or "other" drugs (73% vs. 23%, P < 0.001). In multivariate regression analysis, use of methamphetamine (adjusted odds ratio, 17.8, 95% CI, 5.6-56) was independently associated with the risk of HIV infection. These findings indicate a wide acceptance of HIV counseling and testing and document a higher HIV seroprevalence among pregnant women delivering at Tijuana General Hospital than current established estimates in Mexico.

18 March 2025 in Travel Medicine and Infectious Disease
Verified
Journal Article
Open access
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
MPMaría Camila Puerta-Arias
María Camila Puerta-Arias
RHRola Husni
Rola Husni
JMJuan J. Montenegro-Idrogo
Juan J. Montenegro-Idrogo
JAJuan Pablo Escalera Antezana
Juan Pablo Escalera Antezana
JSJosé Antonio Suárez
José Antonio Suárez

13 April 2021 in Cureus
Verified
Journal Article
Open access
ELErika Zoe Lopatynsky
Erika Zoe Lopatynsky
HAHeidy Acosta-Lazo
Heidy Acosta-Lazo
Rolando Ulloa-GutierrezRolando Ulloa-Gutierrez
Rolando Ulloa-Gutierrez
María L. Ávila-AgueroMaría L. Ávila-Aguero
María L. Ávila-Aguero
Enrique Chacon-CruzEnrique Chacon-Cruz
Enrique Chacon-Cruz
Bacillus Calmette-Guérin (BCG) local scar inflammatory reactions have been mostly associated with Kawasaki disease in children and less commonly with other viral infections (i.e., measles). BCG scar inflammation associated with or following vaccine administration has only been reported with the influenza vaccine. We describe the first reports in the literature of local BCG inflammation following two different available messenger ribonucleic acid (mRNA) anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) vaccines (mRNA-1273, and BNT162b2) in two young healthy physicians, one from Costa Rica, and another from the United States of America, with normal cell blood counts, flow cytometries, and negative for human immunodeficiency virus (HIV). In both cases, BCG scar inflammation appeared after 24 hours of vaccination of the second dose, without signs of reaction on the injection site, and resolved within four days. Dermoscopic findings in one case showed arborizing and comma-shaped vessels. Pharmacovigilance surveillance of BCG scar reactions following coronavirus disease 2019 (COVID-19) vaccines should be considered particularly in countries where BCG is part of their national immunization programs.

1 March 2011 in Emerging Infectious Diseases
Verified
Journal Article
Open access
Enrique Chacon-CruzEnrique Chacon-Cruz
Enrique Chacon-Cruz
DSDavid E. Sugerman
David E. Sugerman
MGMichele M. Ginsberg
Michele M. Ginsberg
JHJackie Hopkins
Jackie Hopkins
JHJose Antonio Hurtado-Montalvo
Jose Antonio Hurtado-Montalvo
JLJohn A. Leake
John A. Leake
We reviewed confirmed cases of pediatric invasive meningococcal disease in Tijuana, Mexico, and San Diego County, California, USA, during 2005–2008. The overall incidence and fatality rate observed in Tijuana were similar to those found in the US, and serogroup distribution suggests that most cases in Tijuana are vaccine preventable.

13 March 2014 in Therapeutic Advances in Vaccines
Verified
Journal Article
Open access
Enrique Chacon-CruzEnrique Chacon-Cruz
Enrique Chacon-Cruz
LMLuz Elena Espinosa-De Los Monteros
Luz Elena Espinosa-De Los Monteros
SNSamuel Navarro-Alvarez
Samuel Navarro-Alvarez
JAJose Luis Aranda-Lozano
Jose Luis Aranda-Lozano
MVMaria Luisa Volker-Soberanes
Maria Luisa Volker-Soberanes
JVJulio Alberto Vazquez
Julio Alberto Vazquez
Invasive meningococcal disease (IMD) has been reported to be endemic in children from Tijuana, Mexico and the risk of an outbreak was always a threat. To describe all clinical, epidemiological and microbiological features of a meningococcal outbreak that occurred in Tijuana, Mexico. All cases with IMD were admitted at different emergency departments within the city and diagnosed by culture and agglutination tests. Further restriction fragment length polymorphism pulse field gel electrophoresis (RFLP–PFGE) and multi locus sequence typing (MLST) were performed. All clinical and epidemiological characteristics and interventions were evaluated, as well as risk factors associated with mortality. From 30 January 2013 to 30 March 2013 there were 19 cases of IMD all caused by Neisseria meningitidis serogroup C. The median age was 16 years (2–47), with higher frequency among individuals at least 13 years old (73.7%). At admission, meningitis was the main clinical presentation (94.7%), followed by purpura (78.9%), septic shock (42.1%) and disseminated intravascular coagulation (DIC, 36.8%). Overall mortality was seven (36.8%). Variables associated with higher mortality were, at admission, presence of septic shock, DIC and thrombocytopenia less than 70,000. All 19 cases had no identifiable site or cluster as the source of the outbreak. RFLP-PFGE showed a discriminatory power for only one profile on all N. meningitidis strains analyzed and a clone ST-11 was identified in all strains. Public health interventions were continuous case reporting of all suspected cases of IMD, an increase in active surveillance in all hospitals, training of medical and laboratory personnel, massive and rapid chemoprophylaxis to all close contacts as indicated, and promotion of good health habits. An outbreak with high mortality of IMD occurred in Tijuana, Mexico. This event and evidence of endemicity should encourage health authorities to evaluate meningococcal vaccination in the region.